A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

por Adjei, Alex A., LoRusso, Patricia, Ribas, Antoni, Sosman, Jeffrey A., Pavlick, Anna, Dy, Grace K., Zhou, Xiaofei, Gangolli, Esha, Kneissl, Michelle, Faucette, Stephanie, Neuwirth, Rachel, Bózon, Viviana
Publicado 2016

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

por Rasco, Drew W., Medina, Theresa, Corrie, Pippa, Pavlick, Anna C., Middleton, Mark R., Lorigan, Paul, Hebert, Chris, Plummer, Ruth, Larkin, James, Agarwala, Sanjiv S., Daud, Adil I., Qiu, Jiaheng, Bozon, Viviana, Kneissl, Michelle, Barry, Elly, Olszanski, Anthony J.
Publicado 2023

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

por Comin-Anduix, Begoña, Lee, Yohan, Jalil, Jason, Algazi, Alain, de la Rocha, Pilar, Camacho, Luis H, Bozon, Viviana A, Bulanhagui, Cecile A, Seja, Elisabeth, Villanueva, Arturo, Straatsma, Bradley R, Gualberto, Antonio, Economou, James S, Glaspy, John A, Gomez-Navarro, Jesus, Ribas, Antoni
Publicado 2008